For years, researchers have looked for a solution that would mean fewer injections for those with type 1 diabetes.
Work on a lipid-based carrier that could safely transport insulin through the stomach, before it is absorbed in the bloodstream, was presented today at the 252nd meeting of the American Chemical Society in Philadelphia.
The technology, which researchers call a Cholestosome, is among several concepts being studied for protecting insulin from stomach acids before it reaches the intestines, where it could pass into the bloodstream. The concept would allow insulin to be administered in a pill form instead of injection, a fact of life for persons with diabetes.
Mary McCourt, PhD; Lawrence Mielnicki, PhD, and undergraduate Jamie Catalano of Niagara University presented their concept for a naturally occurring lipid molecule, which differs from other drug carriers under study. “Most liposomes need to be packaged in a polymer coating for protection,” Mielnicki said in a statement. “Here, we’re just using simple lipid esters (or compounds) to make vesicles with the drug molecules inside.”
The team presented computer modeling that showed the lipids assembled into spheres, forming neutral particles that are able to withstand attack from stomach acids. The spheres then reach the intestines, where they are recognized and absorbed. Once in the bloodstream, they break apart, and the insulin is released.
Researchers tested several insulin doses and pH levels until they found the optimal levels for animal testing. So far, tests with rats show that the insulin travels properly in the bloodstream, a concept known as “bioavailability,” or getting the drug where it needs to be. More tests are needed to fine-tune insulin levels before human trials can begin.
For years, diabetes researchers have looked for treatments to reduce the number of insulin injections, especially for children with type 1 disease at school or day care, where a nurse or other third party must administer insulin until the child is old enough for self-care. The inhaled insulin Afrezza has received enthusiastic reviews from patients, but some doctors have been reluctant to prescribe it due to concerns about the effect on the lungs, as well as FDA requirement for spirometry. Payer coverage has also been difficult for many patients.
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Read More
Advancements in Diabetes Technology: Coverage, Challenges, and Pregnancy Considerations
February 15th 2024Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.
Read More